Uncategorized
AAO airs concerns about beyond-use dates for repackaged Avastin
The American Academy of Ophthalmology has provided comments to the FDA expressing its concern that beyond-use dates for repackaged Avastin may limit the drug’s availability for the treatment of age-related macular degeneration.The beyond-use dates (BUDs) were included in one of five draft guidance documents issued by the FDA in February to clarify provisions of the Drug Quality and Security Act and Compounding Quality Act. The laws were passed in 2013 in the wake of infectious outbreaks traced to steroids and repackaged Avastin provided at compounding pharmacies.